BCL2L11 and non-small cell lung carcinoma: Additionally, we also found that TKI therapy in mutated-EGFR NSCLC showed inferiority of patients carrying BIM deletion polymorphism over BIM wild polymorphism in term of PFS in both univariate and multivariate analyses, indicating that BIM deletion polymorphism was an independent prognostic factor for advanced EGFR-mutated NSCLC with TKI therapy.